<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04856488</url>
  </required_header>
  <id_info>
    <org_study_id>LugolProtocol001</org_study_id>
    <nct_id>NCT04856488</nct_id>
  </id_info>
  <brief_title>Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter</brief_title>
  <official_title>Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jan Calissendorff</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess if preoperative treatment with Lugol's solution prior&#xD;
      to thyroidectomy can reduce the surgical complications hypoparathyroidism and laryngeal nerve&#xD;
      palsy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current practice in Sweden before thyroidectomy due to hyperthyroidism is preoperative&#xD;
      treatment with antithyroid drugs (ATD) to all patients with Graves' disease and in cases of&#xD;
      toxic nodular goiter with pronounced hyperthyroidism. Iodine solution is administered&#xD;
      preoperatively in selected cases of Graves' disease where ATD is intolerable. In the cases&#xD;
      where iodine is used it is in the form of extemporaneous prepared iodine potassium iodide&#xD;
      solution (Lugol 5%). The dose varies in clinical studies. In American and Swedish guidelines&#xD;
      the dose is 5-10 drops 3 times per day for 10 days prior to surgery. American guidelines&#xD;
      recommend iodine as preoperative treatment i Graves' disease but this is based on sparse&#xD;
      evidence. Iodine as preoperative treatment in toxic nodular goiter has yet not been studied.&#xD;
&#xD;
      The purpose of this study is to assess if preoperative treatment with Lugol's solution prior&#xD;
      to thyroidectomy due to hyperthyroidism reduce the surgical complications hypoparathyroidism&#xD;
      and laryngeal nerve palsy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Temporary hypoparathyroidism</measure>
    <time_frame>1 month postoperatively</time_frame>
    <description>Numbers of participants with signs of hypoparathyroidism measured as hypocalcemia, low parathormone (PTH), supplementation with per oral vitamin D or calcium.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Temporary laryngeal nerve palsy</measure>
    <time_frame>1 month postoperatively</time_frame>
    <description>Number of patients with postoperative signs of vocal chord damage via clinical assessment or laryngoscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Permanent laryngeal nerve palsy</measure>
    <time_frame>6 months postoperatively</time_frame>
    <description>Number of patients with postoperative signs of vocal chord damage via clinical assessment or laryngoscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Permanent hypoparathyroidism</measure>
    <time_frame>6 months postoperatively</time_frame>
    <description>Numbers of participants with signs of hypoparathyroidism measured as hypocalcemia, low PTH, supplementation with per oral vitamin D or calcium.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from Baseline in Quality of Life on the Thyroid Specific Patient Reported Outcome 39 (ThyPRO 29) questionnaire</measure>
    <time_frame>6 months postoperatively</time_frame>
    <description>ThyPRO 39 is a validated thyroid specific Quality of Life form. Self reported questionnaire filled out before and after surgery. ThyPRO consists of 39 items grouped in 11 scales. Each item is is rated from 0 to 5 on a 5 point Likert scale. Increasing scores indicating decreasing quality of life. Lower scores indicating better quality of life.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">182</enrollment>
  <condition>Hyperthyroidism</condition>
  <arm_group>
    <arm_group_label>Iodine Potassium Iodide solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Iodine Potassium Iodide solution oral drops 3 times per day for 10 Days prior to thyroidectomy in addition to standard preoperative treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants continue with standard preoperative treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iodine-Potassium Iodide 5%-10% Oral and Topical Solution</intervention_name>
    <description>Iodine Potassium Iodide 5% oral solution, administered 3 times per day for 10 days</description>
    <arm_group_label>Iodine Potassium Iodide solution</arm_group_label>
    <other_name>Lugol's solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hyperthyroidism accepted for thyroidectomy due to toxic nodular goiter with free T4&#xD;
             &lt;30 pmol/L or Graves' disease&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable coronary artery disease&#xD;
&#xD;
          -  Previous thyroid surgery&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Renal insufficiency&#xD;
&#xD;
          -  Hepatic failure&#xD;
&#xD;
          -  Current infection&#xD;
&#xD;
          -  Treatment with steroids or anticoagulants&#xD;
&#xD;
          -  Thyroid associated orbitopathy CAS &gt; 2&#xD;
&#xD;
          -  Diabetes mellitus type 1&#xD;
&#xD;
          -  Active cancer&#xD;
&#xD;
          -  Severe psychiatric illness&#xD;
&#xD;
          -  Amiodarone treatment&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
          -  Women of child bearing potential not using contraceptive&#xD;
&#xD;
          -  Inability to comprehend the meaning of the study&#xD;
&#xD;
          -  Iodine hypersensitivity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Calissendorff, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Molecular Medicine and Surgery, Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan Calissendorff, MD, PhD</last_name>
    <phone>+46(0)8 51770000</phone>
    <email>jan.calissendorff@sll.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fredric Hedberg, MD</last_name>
    <phone>+46(0)8 51770000</phone>
    <email>fredric.hedberg@sll.se</email>
  </overall_contact_backup>
  <reference>
    <citation>Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-1421. Erratum in: Thyroid. 2017 Nov;27(11):1462.</citation>
    <PMID>27521067</PMID>
  </reference>
  <reference>
    <citation>Kaur S, Parr JH, Ramsay ID, Hennebry TM, Jarvis KJ, Lester E. Effect of preoperative iodine in patients with Graves' disease controlled with antithyroid drugs and thyroxine. Ann R Coll Surg Engl. 1988 May;70(3):123-7.</citation>
    <PMID>2457351</PMID>
  </reference>
  <reference>
    <citation>Randle RW, Bates MF, Long KL, Pitt SC, Schneider DF, Sippel RS. Impact of potassium iodide on thyroidectomy for Graves' disease: Implications for safety and operative difficulty. Surgery. 2018 Jan;163(1):68-72. doi: 10.1016/j.surg.2017.03.030. Epub 2017 Nov 3.</citation>
    <PMID>29108701</PMID>
  </reference>
  <reference>
    <citation>Whalen G, Sullivan M, Maranda L, Quinlan R, Larkin A. Randomized trial of a short course of preoperative potassium iodide in patients undergoing thyroidectomy for Graves' disease. Am J Surg. 2017 Apr;213(4):805-809. doi: 10.1016/j.amjsurg.2016.07.015. Epub 2016 Aug 4.</citation>
    <PMID>27769543</PMID>
  </reference>
  <reference>
    <citation>Marigold JH, Morgan AK, Earle DJ, Young AE, Croft DN. Lugol's iodine: its effect on thyroid blood flow in patients with thyrotoxicosis. Br J Surg. 1985 Jan;72(1):45-7.</citation>
    <PMID>3967130</PMID>
  </reference>
  <reference>
    <citation>Yilmaz Y, Kamer KE, Ureyen O, Sari E, Acar T, Karahalli O. The effect of preoperative Lugol's iodine on intraoperative bleeding in patients with hyperthyroidism. Ann Med Surg (Lond). 2016 Jun 16;9:53-7. doi: 10.1016/j.amsu.2016.06.002. eCollection 2016 Aug.</citation>
    <PMID>27408715</PMID>
  </reference>
  <reference>
    <citation>Huang SM, Liao WT, Lin CF, Sun HS, Chow NH. Effectiveness and Mechanism of Preoperative Lugol Solution for Reducing Thyroid Blood Flow in Patients with Euthyroid Graves' Disease. World J Surg. 2016 Mar;40(3):505-9. doi: 10.1007/s00268-015-3298-8.</citation>
    <PMID>26546192</PMID>
  </reference>
  <reference>
    <citation>Calissendorff J, Falhammar H. Rescue pre-operative treatment with Lugol's solution in uncontrolled Graves' disease. Endocr Connect. 2017 May;6(4):200-205. doi: 10.1530/EC-17-0025. Epub 2017 Mar 21.</citation>
    <PMID>28325735</PMID>
  </reference>
  <reference>
    <citation>Calissendorff J, Falhammar H. Lugol's solution and other iodide preparations: perspectives and research directions in Graves' disease. Endocrine. 2017 Dec;58(3):467-473. doi: 10.1007/s12020-017-1461-8. Epub 2017 Oct 26. Review.</citation>
    <PMID>29075974</PMID>
  </reference>
  <reference>
    <citation>Spallek L, Krille L, Reiners C, Schneider R, Yamashita S, Zeeb H. Adverse effects of iodine thyroid blocking: a systematic review. Radiat Prot Dosimetry. 2012 Jul;150(3):267-77. doi: 10.1093/rpd/ncr400. Epub 2011 Oct 20. Review.</citation>
    <PMID>22021061</PMID>
  </reference>
  <reference>
    <citation>Nauman J, Wolff J. Iodide prophylaxis in Poland after the Chernobyl reactor accident: benefits and risks. Am J Med. 1993 May;94(5):524-532. doi: 10.1016/0002-9343(93)90089-8.</citation>
    <PMID>8498398</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Jan Calissendorff</investigator_full_name>
    <investigator_title>MD, Senior Consultant, PhD, Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graves Disease</mesh_term>
    <mesh_term>Hyperthyroidism</mesh_term>
    <mesh_term>Goiter, Nodular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lugol's solution</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The original contributions presented in the study are included in the article/supplementary material.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>The original contributions presented in the study are included in the article/supplementary material. Inquiries can be directed to the corresponding author after publication.</ipd_time_frame>
    <ipd_access_criteria>Further inquiries can be directed to the corresponding author.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

